Company Filing History:
Years Active: 2017-2020
Title: Michael Quirk: Innovator in NMDA Antagonist Prodrugs
Introduction
Michael Quirk is a notable inventor based in Acton, MA (US). He has made significant contributions to the field of pharmacology, particularly in the development of NMDA antagonist prodrugs. With a total of 3 patents to his name, Quirk's work focuses on innovative treatments for depression and pain management.
Latest Patents
Quirk's latest patents include the development of prodrugs of an NMDA antagonist, specifically (S)-1-phenyl-2-(pyridin-2-yl)ethanamine. These prodrugs are designed to be useful for the treatment of major depressive disorder and pain. The compositions comprising these prodrugs and the methods of making them represent a significant advancement in therapeutic options for patients.
Career Highlights
Throughout his career, Michael Quirk has been associated with AstraZeneca AB, where he has contributed to various research initiatives. His work has been instrumental in advancing the understanding and treatment of mental health disorders.
Collaborations
Quirk has collaborated with notable colleagues such as Gunnar Nordvall and Per Jonas Malmborg. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Michael Quirk's contributions to the field of pharmacology, particularly through his patents on NMDA antagonist prodrugs, highlight his role as an influential inventor. His work continues to pave the way for new treatment options in mental health and pain management.